Table 1. Reactivity of anti-LPAP and anti-CD45 mAb with human primary and transformed cells.
| LPAP | CD45 | |
|---|---|---|
| Transfectants | ||
| HEK293-mock | − | − |
| HEK293-LPAP | +++ | − |
| Primary cells | ||
| Peripheral blood lymphocytes | +++ | +++ |
| Peripheral blood monocytes | − | +++ |
| Peripheral blood neutrophils | − | ++ |
| Thymocytes | +++ | ++ |
| Monocyte-derived immature dendritic cells | − | |
| Monocyte-derived stimulated dendritic cells | − | |
| Erythrocytes | − | − |
| Cell lines | ||
| Jurkat (T-cell leukemia) | +++ | +++ |
| CEM (acute T lymphoblastic leukemia) | +++ | +++ |
| HUT78 (T cell lymphoma) | +++ | +++ |
| MOLT-4 (acute lymphoblastic leukemia) | ++ | + |
| HPB-ALL (T cell lymphoma) | − | − |
| DAUDI (Burkitt's lymphoma) | ++ | +++ |
| Raji (Burkitt's lymphoma) | ++ | +++ |
| Ramos (Burkitt's lymphoma) | ++ | +++ |
| CCRF-SB (acute lymphoblastic leukemia) | + | ++ |
| IM-9 (multiple myeloma) | ++ | +++ |
| RPMI 1788 (B lymphocytes) | − | + |
| Reh (pro-B leukemia) | ++ | +++ |
| NALM-6 (pro-B leukemia) | − | − |
| RPMI 8266 (myeloma) | − | − |
| U266 (myeloma) | − | ++ |
| YT (NK leukemia) | +++ | +++ |
| HL-60 (AML-M2) | + | ++ |
| THP-1 (AML-M5) | − | ++ |
| MONO-MAC-6 (AML-M5) | − | +++ |
| U-937 (histiocytic lymphoma) | − | ++ |
| K-562 (CML-erythroblast) | − | +++ |
| Cell lines (solid tumors) | ||
| Hep G2 (hepatocellular carcinoma) | − | − |
| MCF7 (adenocarcinoma) | − | − |
Abbreviation: MFI, mean fluorescence intensity.
Scores: (−) MFI<50; (+) 50<MFI<100; (++) 100<MFI<200; (+++) 200<MFI.